Last reviewed · How we verify
Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV is a Small molecule drug developed by University of KwaZulu. It is currently FDA-approved.
At a glance
| Generic name | Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV |
|---|---|
| Sponsor | University of KwaZulu |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV CI brief — competitive landscape report
- Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV updates RSS · CI watch RSS
- University of KwaZulu portfolio CI
Frequently asked questions about Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
What is Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV?
Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV is a Small molecule drug developed by University of KwaZulu.
Who makes Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV?
Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV is developed and marketed by University of KwaZulu (see full University of KwaZulu pipeline at /company/university-of-kwazulu).
What development phase is Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV in?
Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV is FDA-approved (marketed).